Patrick Thomas Gunning active positions
| Companies | Position | Start | End |
|---|---|---|---|
Dunad Therapeutics Ltd.
 Dunad Therapeutics Ltd. BiotechnologyHealth Technology Dunad Therapeutics Ltd. is a British biopharmaceutical company that specializes in developing targeted protein degradation therapies. Dunad was founded in 2020 and is headquartered in an undisclosed location, with operations in both the UK and the US. The company's platform allows for selective degradation through direct target modification using tuneable mono-valent small molecules, which enables the development of more drug-like, orally bioavailable, and CNS-accessible protein degraders. The company is backed by Epidarex Capital. Pearl Shirley Huang has been the CEO of the company since 2022. | Director/Board Member | - | - |
| Chief Tech/Sci/R&D Officer | - | - | |
| Founder | - | - | |
| Chief Executive Officer | - | - |
Career history of Patrick Thomas Gunning
Statistics
International
| United Kingdom | 2 |
Operational
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Dunad Therapeutics Ltd.
Dunad Therapeutics Ltd. BiotechnologyHealth Technology Dunad Therapeutics Ltd. is a British biopharmaceutical company that specializes in developing targeted protein degradation therapies. Dunad was founded in 2020 and is headquartered in an undisclosed location, with operations in both the UK and the US. The company's platform allows for selective degradation through direct target modification using tuneable mono-valent small molecules, which enables the development of more drug-like, orally bioavailable, and CNS-accessible protein degraders. The company is backed by Epidarex Capital. Pearl Shirley Huang has been the CEO of the company since 2022. | Health Technology |
